Design Therapeutics (DSGN) Stock Price, News & Analysis

Company Overview

Design Therapeutics, Inc. is a clinical-stage biotechnology company developing small-molecule medicines for genetic diseases. The company’s research platform, known as GeneTACs (Gene Targeted Chimeras), is designed to reactivate genes that have been silenced or disrupted by pathogenic genetic changes.

Design Therapeutics’ lead programs have focused on diseases associated with nucleotide repeat expansions. Its pipeline has included DT-216, an investigational therapy intended to restore production of the frataxin protein in patients with Friedreich’s ataxia, a rare inherited neurological disorder. The company has also advanced GeneTAC research for additional genetic conditions, including ophthalmic diseases.

Founded in 2017 and headquartered in Carlsbad, California, Design Therapeutics conducts drug discovery and clinical development primarily in the United States. The company was co-founded and is led by Pratik Shah, Ph.D., who serves as president and chief executive officer. Its products remain investigational and are subject to clinical and regulatory evaluation.

Key Stats

• Today's Range: $12.12 to $13.25
• 50-Day Range: $11.63 to $15.94
• 52-Week Range: $5.28 to $17.25
• Volume: 738,274 shs
• Average Volume: 770,108 shs
• Market Capitalization: $773.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.50
• Consensus Rating: Moderate Buy

Design Therapeutics Stock Analysis - MarketRank™

Design Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 448th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Design Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Design Therapeutics has a consensus price target of $16.50, representing about 33.5% upside from its current price of $12.36.

Amount of Analyst Coverage

Design Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Design Therapeutics are expected to decrease in the coming year, from ($1.41) to ($1.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Design Therapeutics is -10.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Design Therapeutics is -10.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Design Therapeutics has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.68% of the float of Design Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Design Therapeutics has a short interest ratio ("days to cover") of 8.98.

Change versus previous month

Short interest in Design Therapeutics has recently decreased by 6.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Design Therapeutics does not currently pay a dividend.

Dividend Growth

Design Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for DSGN on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Design Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.10% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DSGN
• CIK: 1807120
• Web: www.designtx.com
• Phone: 858-293-4900
• Fax: N/A
• Employees: 55
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Design Therapeutics: $16.50
• High Price Target: $21.00
• Low Price Target: $14.00
• Potential Upside/Downside: +33.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -34.03%
• Return on Assets: -32.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.86
• Quick Ratio: 18.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.73 per share
• Price / Book: 3.31

Miscellaneous

• Outstanding Shares: 62,580,000
• Free Float: 51,880,000
• Market Cap: $773.49 million
• Optionable: Optionable
• Beta: 1.66